Clinical trial NCT06843122: Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot (FOOTCELL)
Official title: Evaluation of the Safety and Efficacy of an Advanced Therapy Medicinal Product Containing Live ASCs in the Treatment of Diabetic Foot Syndrome - a Double-blind, Randomized Study.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Diabetic Foot Ulcer
Keywords: adipose-derived mesenchymal stem cells
chronic wounds
diabetes
foot ulcer
Lead sponsor: Medical University of Warsaw
Sponsor class: OTHER
Collaborators: name: Medical Research Agency, Poland
First posted: 2025-02-24
Enrollment: 105
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients will be allocated to one of the following arms: Double administration of ADSC/ASC, single administration of ADSC/ASC or Placebo (control) all in addition to SOC treatment
Primary purpose: OTHER

Brief summary: The goal of this study is to investigate the safety and efficacy of allogenic mesenchymal stem cells isolated from adipose tissue as the treatment for chronic wounds in diabetic foot syndrome in a double-blinded three armed setup.

Detailed description: Patients will be randomized and assigned to one of three study groups, and will receive according IMP solutions: 1) two doses of cell solution; 2) one dose of cell solution and one dose of placebo solution; 3) two doses of placebo solutions. During the study Patients will attend to weekly visits for routine monitoring and SOC treatment. The IMP solutions will be administered in two weeks intervals, on day 0 and day 14 of the treatment, and the control visits are scheduled on days 7, 21, 28, 35 and 42 - for a total of 7 visits during the active phase of the study. The follow-up visits will be performed 8, 26 and 52 weeks after the last visit in the active phase (day 42).

Eligibility criteria: Inclusion Criteria:

1. Age \>18 years at the time of consent,
2. The patient's psychophysical and legal ability to give informed consent to participate in the study,
3. Signing the informed consent document for participation in the study,
4. Ulcer classified as diabetic foot syndrome (DFS) of neuropathic and/or neuroischemic etiology corresponding to grade IA/IIA and IC/IIC according to the University of Texas classification (Appendix E),
5. Duration of the ulcer not less than 6 weeks,
6. Presence of a wound with an area of 1-25 cm² (after wound debridement),
7. Satisfactory blood supply to the wound area:

   * assessed using transcutaneous oxygen pressure measurement, if its value is not less than 30 mmHg,
   * or measurement of systolic blood pressure at the posterior tibial artery and/or dorsalis pedis artery, which is not less than 50 mmHg, to exclude patients who require revascularization therapy,
8. Glycated hemoglobin (HbA1c) \< 11%,
9. General health status of the patient, which in the investigator's opinion allows participation in all study procedures,
10. Use of the wound offloading method recommended by the investigator,
11. Use of effective contraception methods to avoid pregnancy (see also Appendix F) and/or based on the following criteria:

    * a woman who is unable to have children (after a hysterectomy or bilateral oophorectomy or post-menopause, defined as a period of at least 12 months since the last menstrual period) is exempt from pregnancy tests,
    * a woman able to have children with a negative pregnancy test result before the administration of the investigational product on the first day and who agrees to periodic pregnancy testing according to the study protocol and to use highly effective contraceptive methods for one month after the end of the active phase of the study (from V6), or two months after the last administration of the investigational drug (from V2).

Exclusion Criteria:

1. Etiology of the ulcer other than diabetic foot syndrome,
2. Presence of an active infection in the wound at the time of inclusion in the study,
3. Wound area \<1 cm² or \>25 cm²,
4. The patient was enrolled in another clinical trial within the 4 weeks preceding the qualification for this study.
5. Clinically significant limb ischemia:

   * assessed using transcutaneous oxygen pressure measurement, if its value is lower than 30 mmHg
   * or measurement of systolic blood pressure at the posterior tibial artery and/or dorsalis pedis artery, if it is lower than 50 mmHg,
6. Presence of an active phase of Charcot joint,
7. Suspected osteitis and/or osteomyelitis within the study wound,
8. Revascularization procedure on the affected lower limb within 3 months prior to study inclusion or planned revascularization procedure,
9. Chronic kidney disease with GFR \< 20 ml/min,
10. Pregnancy and lactation,
11. Allergy to thrombin,
12. Active venous thrombosis,
13. Systemic diseases in the exacerbation stage (acute or decompensated), including heart, kidney, and liver diseases,
14. Active alcohol disease or addiction to psychoactive substances,
15. Allergies to dressing materials used in the study,
16. Oral/intravenous antibiotic therapy at the time of inclusion in the study,
17. Patient undergoing immunosuppressive therapy, including corticosteroid therapy (within 30 days prior to study inclusion),
18. Active cancer or cancer disease in the last 5 years, excluding locally malignant cancers not involving foot tissues,
19. Presence of known clinically active, uncontrolled infections such as hepatitis B, hepatitis C, HIV, and venereal disease (syphilis),
20. Significant features of malnutrition additionally impairing the healing process, regardless of the cause (albumin \< 2.5 g/dl and total protein \< 5 g/dl),
21. Hemoglobin levels \< 9 g/dl,
22. Serum transaminase (alanine and aspartate) activity higher 3x the upper limit of normal (locally).

Primary outcomes:
measure: Change in wound size (%) at 6 weeks after first study treatment administration compared to baseline with the actual wound size measured by the independent assessor.
timeFrame: 6 weeks after the first administration
measure: Type, frequency and severity of adverse events (assessed according CTCAE v5.0); change from baseline of laboratory parameters and selected vital signs of the participants.
timeFrame: 6 weeks after the first administration
Secondary outcomes:
measure: Early efficacy of the allogenic ADSC/ASC defined as percentage of patients with significant clinical success defined as complete wound closure (100% epithelialization), or partial epithelialization of the wound (>50% epithelialization)
timeFrame: 6 weeks after the first administration
measure: Long-term efficacy of the allogenic ADSC/ASC defined as percentage of patients with significant clinical success defined as complete wound closure (100% epithelialization), or partial epithelialization of the wound (>50% epithelialization) over time.
timeFrame: Through study completion, an average of 1 year
measure: The dynamics of wound healing defined as the time required for patients to reach the wound size reduction thresholds: 50% reduction of the wound; maximum reduction of the wound area (%); complete wound healing .
timeFrame: 6 weeks after the first administration and through study completion, an average of 1 year
measure: Absolute change in the wound-associated pain perception over time assessed by the patient using visual analogue scale.
timeFrame: 6 weeks after the first administration and through study completion, an average of 1 year
measure: Additional safety parameters such as wound infection requiring antibiotic treatment expressed as total number of patients, and number of antibiotic therapies per patient.
timeFrame: 6 weeks after the first administration and through study completion, an average of 1 year .
measure: Changes in quality of life parameters assessed by the dedicated QoL questionnaire.
timeFrame: 6 weeks after the first administration and through study completion, an average of 1 year
Other outcomes:
measure: Evaluation of the additional safety and efficacy parameters such as the percentage of patients requiring lower or upper limb amputation or the percentage of patients experiencing CVD events (CVD death, hospitalization for CVD reason)
timeFrame: through study completion, an average of 1 year
Locations:
Study officials:
affiliation: Bielanski Hospital
name: Beata Mrozikiewicz-Rakowska, Assoc.Prof.
role: PRINCIPAL_INVESTIGATOR
References: